Creative BioTherapeutics: Turning Hope into Breakthroughs
When Dr. Donald Davidson walked through the door one evening nearly 30 years ago, he looked at his wife quietly before saying words that would change the course of their lives: “I think I found a cure for brain cancer today.”
That spark ignited what would eventually become Creative BioTherapeutics (CBT), a company focused on tackling one of medicine’s toughest battles drug-resistant cancers. The road wasn’t straightforward. Donald’s promising project was shelved at big pharma, and for years he pursued other therapies while his wife, Dr. Anita Davidson, a seasoned healthcare provider and entrepreneur, urged him to revisit that early breakthrough. Finally, in 2016, the couple took the leap. The very next day, they incorporated Creative BioTherapeutics LLC staying true to the “Creative” branding of their earlier ventures.
Dr. Anita Davidson, CEO/Co-founder Donald Davidson, CSO/Co-founder
Building as a Calling
For Anita, leading Creative BioTherapeutics is not just a career shift; it’s the culmination of decades spent in healthcare, business development, and patient advocacy.
“I’ve always been a builder,” she explains. “I see possibilities where others don’t, and I’ve spent my career challenging the status quo to improve access and quality of care. Now, at CBT, I bring that same drive into drug development. Every step we take is also in memory of the patients I’ve cared for and the ones still waiting for hope.”
The Science Behind CBT300
At the center of the company’s pipeline is CBT300, a therapy described as “first-in-class.” What sets it apart is its ability to target a survival mechanism unique to cancer cells.
“When cancer develops, cells push a particular protein to their surface a kind of protective shield,” Anita explains. “It’s not present on healthy cells, but it helps diseased ones resist drugs, evade the immune system, and survive.”
CBT300 was designed to eliminate that protein, dismantling several cancer survival strategies at once. Unlike traditional therapies, it leaves normal cells untouched, meaning it’s non-toxic, in addition to reversing drug resistance, boosting immune response, and inducing cancer cell death. It’s a multi-pronged attack, one that could work alone or alongside other treatments.
Why Focus on Drug-Resistant Cancers?
The choice wasn’t just scientific; it was deeply personal and practical. Each year, cancer claims more than 10 million lives worldwide, and over 7.5 million of those deaths are due to treatment resistance.
“Donald has always wanted to understand why cancers come back, how they resist, and what really drives poor survival rates,” says Anita. “By starting at the ‘result’ and working backward, he’s developed a unique understanding of disease pathways that could finally tip the scales.”
Proof in the Data and in “Buster”
While much of biotech runs on promise, Creative BioTherapeutics already has results that turn heads.
Early animal studies showed no toxicity and a 70% survival rate in triple-negative breast cancer models. In another study, CBT300 delivered a 68% tumor regression and strong immune response, outperforming chemotherapy. In another study with human Glioblastoma tumors in mice, CBT300 showed a 60% cure rate and overall 78% regression.
Then came the case of Buster, a dog with an aggressive brain tumor. “He was at death’s door when we started,” recalls Anita. “After a few doses of CBT300, his labs normalized, his neurological function returned, and by day 70 he was running around, living his best life. He’s not out of the woods, but his bright eyes remind us every day why we’re doing this.”
The Road Ahead
With patents secured, proof-of-concept data completed, and GMP drug banking in place, Creative BioTherapeutics is preparing for human trials. Pending funding, the company aims to file an Investigational New Drug (IND) application with the FDA by late 2025 or early 2026, with combined Phase I/II trials for drug-resistant brain and breast cancers beginning soon after. If successful, they anticipate market entry by 2028.
Given the urgent need for new solutions in recurrent and resistant cancers, the company will also pursue Fast Track and Breakthrough Therapy designations to accelerate the path.
Powered by Partnerships
No biotech succeeds in isolation, and Creative BioTherapeutics’ journey has been fueled by early believers. “Our first four investors each gave $25,000 gifts,” Anita recalls. “They didn’t just fund us they validated us. Every step forward has been built on shoulders like theirs.”
Even amid a slowdown in biotech funding, the company has pressed on, supported by grants, advisors, and a growing circle of collaborators. As clinical trials approach, they are open to partnerships with larger pharma companies to scale their impact.
Patients at the Center
For Anita, the science is only half the story. The other half is deeply human.
“I keep pictures of my patients on my desk,” she says softly. “It’s a daily reminder that our work is not about numbers or charts it’s about people. Every milestone we hit means another patient could live longer, live better, or even be cured.”
Lessons in Resilience
Building a biotech company has not been without hurdles. Funding delays have been particularly tough, forcing the team to learn patience and persistence. “I’ve always said experience comes from failure and I’m very experienced,” Anita laughs. Yet these setbacks have sharpened her skills in grant writing, investor relations, and biotech strategy, leaving the company stronger than before.
Looking 10 Years Ahead
The company’s vision stretches far beyond a single therapy. “If CBT300 succeeds, I believe we’ll change the way science looks at treatment resistance,” says Anita. “Instead of just treating symptoms, researchers will ask bigger questions why does disease survive, and how can we stop it at the source?”
She hopes one day, the 40,000 women lost each year to metastatic breast cancer will be part of history, not statistics.
Creative BioTherapeutics may be a young company, but its roots run deep in decades of research, advocacy, and resilience. With CBT300 advancing toward the clinic, Anita and her team are chasing a goal that began in a family kitchen three decades ago — not just extending life but rewriting the future of cancer care.
Company Name : Creative BioTherapeutics LLC
website : https://www.creativebio.tech/
Management Team
Dr. Anita Davidson | CEO/Co-founder
Donald Davidson | CSO/Co-founder
